Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

482
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

719
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
719
Menopause01:28

Menopause

5.0K
Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
5.0K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

611
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
611
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

888
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
888
Hemorrhagic Stroke ll: Pathophysiology01:29

Hemorrhagic Stroke ll: Pathophysiology

14
A hemorrhagic stroke develops when a cerebral blood vessel ruptures, allowing blood to escape into the surrounding brain tissue, as in intracerebral hemorrhage (ICH), or into the subarachnoid space, as in subarachnoid hemorrhage (SAH). Because the skull is a rigid compartment, the sudden presence of extravascular blood rapidly increases intracranial pressure and compresses adjacent neural structures, leading to immediate tissue injury and impaired cerebral perfusion.Mass Effect and Primary...
14

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dopamine transporter and beyond: evolving targets and combination strategies in stimulant use disorder.

Expert opinion on pharmacotherapy·2026
Same author

Novel stem cell therapy for cerebral palsy using stem cells from human exfoliated deciduous teeth.

Stem cell research & therapy·2026
Same author

The intake of monosodium aspartate attenuates aggression induced by post-weaning social isolation in an ADHD rat model.

The journal of physiological sciences : JPS·2026
Same author

Neonatal hyperoxia exposure causes cerebellar lesions and behavioral abnormalities in rats.

Scientific reports·2026
Same author

Combination Lorcaserin and Betahistine Treatment Improves Cognitive Dysfunction and Dopaminergic Neuron Activity in a Rat Model of Diet-Induced Obesity.

Brain sciences·2025
Same author

Intracolonic Migration of a Dislocated Acetabular Cup Prosthesis.

HCA healthcare journal of medicine·2025

Related Experiment Video

Updated: Apr 27, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

11.7K

ESTROGEN REPLACEMENT THERAPY FOR STROKE.

Mibel Pabon1, Cyrus Tamboli1, Sarosh Tamboli1

  • 1Department of Neurosurgery and Brain Repair, University of South Florida Morsani College of Medicine, 12901 Bruce B. Downs Blvd., Tampa, FL USA.

Cell Medicine
|July 8, 2014
PubMed
Summary
This summary is machine-generated.

Estrogen (E2) may protect against stroke, potentially mediated by estrogen receptors (ER). This study uses a rat model to investigate E2

More Related Videos

Ovariectomy and 17β-estradiol Replacement in Rats and Mice: A Visual Demonstration
06:51

Ovariectomy and 17β-estradiol Replacement in Rats and Mice: A Visual Demonstration

Published on: June 7, 2012

58.0K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.2K

Related Experiment Videos

Last Updated: Apr 27, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

11.7K
Ovariectomy and 17β-estradiol Replacement in Rats and Mice: A Visual Demonstration
06:51

Ovariectomy and 17β-estradiol Replacement in Rats and Mice: A Visual Demonstration

Published on: June 7, 2012

58.0K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.2K

Area of Science:

  • Neuroscience
  • Endocrinology
  • Pharmacology

Background:

  • Stroke is a leading cause of death and disability, with higher incidence in men.
  • Estrogen (E2) appears protective against stroke, particularly in women, suggesting a role for estrogen receptors (ER).
  • Changes in ER levels during aging and stress may influence stroke susceptibility and treatment response.

Purpose of the Study:

  • To discuss an animal model for investigating the therapeutic effects of E2 and its derivatives in stroke.
  • To test the hypothesis that E2 neuroprotection is partly receptor-mediated via specific ER subtypes.
  • To establish a foundation for developing targeted E2-based stroke therapies.

Main Methods:

  • Utilizing a rat model with retroviral gene transfer to express ER subtypes in brain regions vulnerable to stroke (striatum, cortex).
  • Inducing experimental stroke using the middle cerebral artery occlusion (MCAo) method.
  • Evaluating the extent of neuronal damage post-stroke and E2 administration with specific ER subtypes.

Main Results:

  • A reduction in neuronal damage is anticipated when E2 is administered alongside specific ER subtypes.
  • The animal model is expected to help determine optimal E2 dosage and treatment regimens.
  • This model can identify potential E2-like therapeutics and screen additives in commercial E2 preparations.

Conclusions:

  • E2 neuroprotection in stroke is likely receptor-mediated, involving specific ER subtypes.
  • The developed animal model provides a platform for optimizing E2-based stroke therapies.
  • Further research using this model can inform the design of novel drug therapies for stroke.